AstraZeneca to Acquire EsoBiotec for Up to $1B to Enhance Cancer Cell Therapy Capabilities
- bancheta6
- Mar 26
- 1 min read
Cambridge, UK, March 17, 2025 (Reuters) -- AstraZeneca has announced its agreement to acquire Belgium-based biotechnology firm EsoBiotec for up to $1 billion, in a move designed to bolster its cell therapy capabilities, especially for cancer treatments. EsoBiotec's technology enables the genetic modification of immune cells directly within the body, offering the potential for transformative cell therapy that can be completed in minutes, a significant improvement over the current process, which can take weeks. This acquisition is part of AstraZeneca's strategy to enhance its cancer treatment offerings and accelerate innovation in cell therapy.
Read full article here.
Yorumlar